Sharing Decisions in Cancer Care Important but Difficult to Implement
the Cancer Therapy Advisor take:
Medical specialists recognized the importance of sharing the decision-making process with patients but found it to be difficult to implement in practice, according to an article published online in the journal The Oncologist.
In this study, medical specialists were interviewed and a focus group was established. In the focus group, the investigators analyzed the specialists’ opinions regarding shared decision-making, patient involvement, and their applicability in the context of patients with glioblastoma.
Results showed health care professionals considered patient involvement in decision-making to be important; however, most did not follow through with its elements. Furthermore, specialists did not consider stopping treatment to be equal to continuing treatment.
The authors identified preferences of both patients and medical specialists for starting or continuing treatment and specialists’ assumptions of knowing the patients’ desires as being the major barriers to shared decision-making.
The study suggests training be made available for physicians in order to improve communication and patient involvement in the decision-making process, especially for patients with glioblastoma.
Medical specialists recognized the importance of sharing the decision-making process with patients but found it to be difficult to implement in practice.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Immunotherapy in Glioblastoma: Peaks and Pits
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed